Official announcements from Yap Inc. — partnerships, awards, funding, and more.
Press Release
Yap signs a service agreement with Italy's Icarus — adapting an AI that takes the first call at medical institutions for Japan
Yap Inc. has signed a definitive service agreement, dated August 25, 2026, with Icarus S.r.l. (brand name: Icarus Technology), an Italian company providing a voice assistant in which AI answers calls to medical institutions. Following the memorandum of understanding signed on May 28, 2026, Yap now begins the research needed to adapt the service to Japanese healthcare settings. The name for the Japanese market is "Kyoko AI." No launch date in Japan has been decided at this time.
Yap Signs Memorandum of Understanding with Italy's Icarus S.r.l.
Yap Inc. has signed a Memorandum of Understanding (MoU) on a business partnership with Icarus S.r.l. (product brand: Icarus Technology), a company based in Sardinia, Italy. The MoU follows business development meetings in Tokyo, with the support of the Italian Trade Agency (ITA) and Regione Autonoma della Sardegna, and through SusHi Tech Tokyo, hosted by the Tokyo Metropolitan Government, and the venue of Tokyo Innovation Base. Icarus provides a multilingual AI voice assistant that automates patient phone reception for clinics; together the two companies aim to combine this with Yap's healthcare business and AI capabilities to expand in the Japanese market.
Yap Signs Partnership Agreement with Indonesian Digital Biobank Asa Ren
Yap Inc. has signed a business partnership agreement with Asa Ren, an Indonesian digital biobank company. Asa Ren operates Southeast Asia's first AI-powered digital biobank, integrating clinical and genomic data across diverse ethnic groups to advance personalized medicine and drug discovery. The two companies aim to expand awareness and adoption of Asa Ren's digital biobank.
Yap Signs Import Agreement with Bangladesh's UniMed UniHealth — First Bangladeshi Pharma to Enter Japan
Yap Inc. has signed an import agreement with UniMed UniHealth Pharmaceuticals Limited of Bangladesh. The agreement marks the first entry of a Bangladeshi pharmaceutical company into the Japanese market, beginning with Novotin, a biotin-based nutritional supplement.
Healthcare commentary shared by CEO Masaya Yamamoto on NewsPicks.
Platform
Filter by Tag
NewsPicksNovember 10, 2026
コーヒー3杯と認知症リスク―大規模コホート研究の可能性と限界
A large-scale cohort study tracking approximately 130,000 participants for up to 43 years deserves attention from an evidence-quality standpoint. The finding that consuming around three cups of coffee per day is associated with a reduced risk of dementia aligns with the direction of multiple previous observational studies, and I regard it as carrying a certain degree of credibility. That said, careful interpretation is essential. Because this remains an observational study, the association observed between coffee intake and dementia risk does not establish causation. Confounding factors—such as the tendency of health-conscious individuals to drink coffee in moderation—cannot be fully eliminated no matter how rigorously adjustments are made. While basic research does suggest neuroprotective effects from caffeine and chlorogenic acid found in coffee, extrapolating those findings to humans still warrants caution. Given coffee's potential impact on sleep and cardiovascular load, it would be premature to translate these results into a simple behavioral recommendation to 'drink coffee to prevent dementia.' From a public health perspective, what matters is situating coffee consumption within the broader context of one's overall lifestyle.
Dementia PreventionEpidemiology & Cohort StudiesPublic Health
Safety concerns surrounding GLP-1 receptor agonists have long included discussions of pancreatitis and thyroid cancer risk; the latest FDA warning adds non-arteritic anterior ischemic optic neuropathy (NAION)—a condition in which impaired blood flow to the optic nerve can cause vision loss. The evidence, however, warrants careful interpretation: the FDA itself states that the data are "insufficient to establish a causal relationship," and the signal comes from observational studies alone. Because patients prescribed GLP-1 therapies often carry background conditions such as diabetic vascular disease and hypertension—independent risk factors for NAION—confounding has not been ruled out. For clinicians, the appropriate response is not to curtail prescribing reflexively, but to conduct thorough ophthalmic risk assessments and careful follow-up for vulnerable patients. Given the well-established efficacy of this drug class for obesity and type 2 diabetes, an individualized benefit-risk appraisal remains essential. As indications for these agents expand in Japan, building reliable mechanisms for physicians and patients to share this information appropriately will be increasingly important.
Drug SafetyGLP-1 Receptor AgonistsPharmaceutical Regulation
Reports of rising stroke rates among younger adults challenge the long-standing assumption that cardiovascular disease is primarily a problem of old age. Risk factors such as obesity, hypertension, and type 2 diabetes have been spreading to younger generations for some time, and we are now seeing that trend manifest as measurable increases in incidence. Crucially, this is not a uniquely American phenomenon. Westernized diets, declining physical activity, and chronic stress and sleep deprivation represent structural shifts shared across many developed nations—Japan included. Epidemiological data on stroke in younger Japanese adults remains insufficient, and it is entirely possible that a similar pattern is hiding in plain sight. The consequences of stroke in younger people are far-reaching in ways that differ from those in the elderly: the long-term impact on employment and caregiving capacity translates into substantial losses in quality of life and social productivity. From a prevention standpoint, this calls for lowering the effective age threshold for health screenings and guidance programs, and for embedding early risk stratification into routine clinical care. The 'younging' of disease demands that the mindset of healthcare providers evolve to keep pace.
Stroke & Neurological DiseasePreventive Care & Early InterventionLifestyle-Related Disease
The headline figure of 15.1% revenue growth looks like rapid expansion, but context matters: of the ¥13.5 billion increase, ¥9.1 billion came from the China segment, largely due to the consolidation of Shanghai Hongqiao Chinese Medicine Yinpian (driving decoction-piece sales from ¥1.2B to ¥9.7B), with Yomeishu Manufacturing added in September. Organic growth and acquisition-driven growth need to be read separately. The core domestic ethical Kampo business—129 formulations—grew 4.7% to ¥79.8 billion, but what stands out is the volume data: intermediate-period volume rose 4.9%, outpacing value, and actual dispensing volume at medical institutions was up 3.2%. This contrasts with fiscal 2024, when revenue surged 21.9% while volume grew only 0.8%—meaning most of that gain was price-driven. This term, prescriptions themselves appear to be genuinely increasing. Goreisan is a notable bright spot, with value up 15.1% and dispensing volume up 16.2%, reflecting broader adoption for edema, headache, and dizziness. On the profit side, operating income rose 10.1% to ¥18.8 billion, but the domestic segment inched up just 1.4%, with the operating margin slipping 0.8 points to 18.2% due to higher input costs and a greater China revenue mix. The stronger ordinary and net profit figures were partly supported by foreign-exchange gains on loans and negative goodwill. Looking ahead, the ¥46.9 billion capex plan (up 32.7% year-on-year) and ¥173.7 billion in inventories reflect the supply-chain investment needed to sustain volume growth—a natural constraint when raw materials are agricultural. Two questions will define the story going forward: whether the China raw-herb platform can stabilize domestic procurement while generating standalone profit, and whether domestic volume growth can keep pace with rising depreciation after this wave of heavy investment.
One premise first: I do not read this 52% profit increase as straightforward evidence that Japan Catalyst's earning power has recovered. For the first half, revenue came in at ¥233.8 billion (up 16.8% year on year) and operating profit at ¥13.7 billion (up 52.1%). However, the company's own variance analysis shows that while segment profit rose by ¥7.1 billion, inventory valuation improvements contributed ¥9.2 billion—a swing from valuation losses to gains as naphtha prices climbed from ¥64,800/kL to ¥108,400/kL year on year. Strip that out, and underlying profit arguably fell short of the prior year. The picture is even clearer on a quarterly basis: group segment profit dropped from ¥13.5 billion in Q1 to ¥3.2 billion in Q2, with the acrylic acid and SAP segment posting a ¥1.5 billion loss in Q2, partly due to delayed price pass-through, planned maintenance downtime, and—explicitly noted in the materials—a widening price gap caused by Chinese overcapacity. On the positive side, the Solutions business expanded segment profit sharply, from ¥2.7 billion to ¥8.2 billion, supported by wider spreads in amines and surfactants and improved equity-method earnings from battery-related investments—a less market-sensitive earnings base that is worth acknowledging. Full-year operating profit guidance was revised up by ¥1.0 billion to ¥22.0 billion, but the implied second-half figure of ¥8.3 billion is well below the first half's ¥13.7 billion, and if raw-material prices stay elevated, the inventory tailwind will fade. SAP underpins diapers—especially adult diapers whose demand is sustained by an ageing population—making stable supply a genuine concern for care settings. With a 50,000-tonne capacity expansion in Indonesia targeting commercial operations in July 2027, how the company navigates intensifying price competition will be the key question to watch.
One thing to clarify first: the headline figures—operating profit down 77%, interim net profit down 91%—overstate the deterioration in core business performance. The prior-year period included one-off gains of ¥2.8 billion from investment partnership income and ¥2.5 billion from securities sales. Stripping those out, core operating profit (before R&D expenses) fell 37%, from ¥2.23 billion to ¥1.40 billion—still a tough number, compounded by a full-year core operating profit guidance cut from ¥5.7 billion to ¥3.4 billion. The real issue, as I see it, is a structural one: revenue grows, but profit doesn't follow. Net sales rose 3.2% to ¥309.8 billion, driven by high-priced oncology drugs and influenza vaccines, yet the gross margin edged down from 7.94% to 7.86%, with SG&A expenses expanding ¥1.55 billion against only ¥510 million of additional gross profit. The pharmaceutical wholesale segment generated just ¥1.5 billion in segment profit on ¥291.1 billion in sales—a margin of roughly 0.5%—as drug price revisions, lower selling prices, rising purchase costs, and shrinking rebates all weighed simultaneously. My broader view is that as the product mix shifts toward specialty medicines, wholesalers handle larger transaction values but capture an ever-thinner slice: high-priced drugs invite tougher price negotiations while demanding more in cold-chain logistics and medical information services. Rising labor, infrastructure, and cybersecurity costs are difficult to pass on when drug prices are revised downward every year. This dynamic persists as long as wholesale profits depend on drug-price spreads. That is precisely why I want to watch how the company rebalances toward fee-based revenue—its GDP/GMP-compliant 3PL center in Isehara, which earns logistics service fees directly from pharmaceutical manufacturers, and its in-house pharmaceutical development pipeline, which absorbed ¥860 million in costs during the interim period while advancing a Phase 2 trial. Both are tests of whether a wholesaler can evolve from 'a company that moves drugs' to 'a company that sells capabilities.' Two things to monitor going forward: whether the plan to earn roughly ¥2.0 billion in second-half core operating profit—more than the first half—can be achieved through vaccine demand and cost discipline; and whether 3PL and pharmaceutical development begin to register as meaningful contributors that offset the wafer-thin margins of the core wholesale business.
Pharmaceutical WholesaleDrug Pricing PolicyHealthcare Business Strategy